These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 19849863)

  • 1. Expression profiling identifies genes involved in neoplastic transformation of serous ovarian cancer.
    Merritt MA; Parsons PG; Newton TR; Martyn AC; Webb PM; Green AC; Papadimos DJ; Boyle GM
    BMC Cancer; 2009 Oct; 9():378. PubMed ID: 19849863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling.
    Gilks CB; Vanderhyden BC; Zhu S; van de Rijn M; Longacre TA
    Gynecol Oncol; 2005 Mar; 96(3):684-94. PubMed ID: 15721412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.
    Bonome T; Lee JY; Park DC; Radonovich M; Pise-Masison C; Brady J; Gardner GJ; Hao K; Wong WH; Barrett JC; Lu KH; Sood AK; Gershenson DM; Mok SC; Birrer MJ
    Cancer Res; 2005 Nov; 65(22):10602-12. PubMed ID: 16288054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression profiling of mucinous tumors of the ovary identifies genes of clinicopathologic importance.
    Wamunyokoli FW; Bonome T; Lee JY; Feltmate CM; Welch WR; Radonovich M; Pise-Masison C; Brady J; Hao K; Berkowitz RS; Mok S; Birrer MJ
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):690-700. PubMed ID: 16467078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or =5-year) follow-up.
    Longacre TA; McKenney JK; Tazelaar HD; Kempson RL; Hendrickson MR
    Am J Surg Pathol; 2005 Jun; 29(6):707-23. PubMed ID: 15897738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular subtypes of serous borderline ovarian tumor show distinct expression patterns of benign tumor and malignant tumor-associated signatures.
    Curry EW; Stronach EA; Rama NR; Wang YY; Gabra H; El-Bahrawy MA
    Mod Pathol; 2014 Mar; 27(3):433-42. PubMed ID: 23948749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chromosome 3 anomalies investigated by genome wide SNP analysis of benign, low malignant potential and low grade ovarian serous tumours.
    Birch AH; Arcand SL; Oros KK; Rahimi K; Watters AK; Provencher D; Greenwood CM; Mes-Masson AM; Tonin PN
    PLoS One; 2011; 6(12):e28250. PubMed ID: 22163003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy.
    Santin AD; Zhan F; Bellone S; Palmieri M; Cane S; Bignotti E; Anfossi S; Gokden M; Dunn D; Roman JJ; O'Brien TJ; Tian E; Cannon MJ; Shaughnessy J; Pecorelli S
    Int J Cancer; 2004 Oct; 112(1):14-25. PubMed ID: 15305371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential gene expression analysis of ovarian cancer in a population isolate.
    Grazio D; Pichler I; Fuchsberger C; Zolezzi F; Guarnieri P; Heidegger H; Scherer A; Engl B; Messini S; Egarter-Vigl E; Pramstaller PP
    Eur J Gynaecol Oncol; 2008; 29(4):357-63. PubMed ID: 18714569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low malignant potential tumors with micropapillary features are molecularly similar to low-grade serous carcinoma of the ovary.
    May T; Virtanen C; Sharma M; Milea A; Begley H; Rosen B; Murphy KJ; Brown TJ; Shaw PA
    Gynecol Oncol; 2010 Apr; 117(1):9-17. PubMed ID: 20117829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Expression and promotor methylation of p73 gene in ovarian epithelial tumors].
    Zhang YL; Guo XR; Shen DH; Cheng YX; Liang XD; Chen YX; Wang Y
    Zhonghua Bing Li Xue Za Zhi; 2012 Jan; 41(1):33-8. PubMed ID: 22455848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular subtyping of serous ovarian tumors reveals multiple connections to intrinsic breast cancer subtypes.
    Jönsson JM; Johansson I; Dominguez-Valentin M; Kimbung S; Jönsson M; Bonde JH; Kannisto P; Måsbäck A; Malander S; Nilbert M; Hedenfalk I
    PLoS One; 2014; 9(9):e107643. PubMed ID: 25226589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential.
    Meinhold-Heerlein I; Bauerschlag D; Hilpert F; Dimitrov P; Sapinoso LM; Orlowska-Volk M; Bauknecht T; Park TW; Jonat W; Jacobsen A; Sehouli J; Luttges J; Krajewski M; Krajewski S; Reed JC; Arnold N; Hampton GM
    Oncogene; 2005 Feb; 24(6):1053-65. PubMed ID: 15558012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-malignant potential epithelial tumors of the ovary: a clinicopathological study.
    Hassan E; Koumantaki Y; Stefanaki K; Matalliotakis I; Koumantakis E
    Eur J Gynaecol Oncol; 1998; 19(2):170-2. PubMed ID: 9611060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer.
    Ouellet V; Guyot MC; Le Page C; Filali-Mouhim A; Lussier C; Tonin PN; Provencher DM; Mes-Masson AM
    Int J Cancer; 2006 Aug; 119(3):599-607. PubMed ID: 16572426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical profiling of benign, low malignant potential and low grade serous epithelial ovarian tumors.
    Ouellet V; Ling TH; Normandin K; Madore J; Lussier C; Barrès V; Bachvarov D; Rancourt C; Tonin PN; Provencher DM; Mes-Masson AM
    BMC Cancer; 2008 Nov; 8():346. PubMed ID: 19032793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Annexin IV is differentially expressed in clear cell carcinoma of the ovary.
    Miao Y; Cai B; Liu L; Yang Y; Wan X
    Int J Gynecol Cancer; 2009 Dec; 19(9):1545-9. PubMed ID: 19955935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression profile of tight junction protein claudin 3 and claudin 4 in ovarian serous adenocarcinoma with prognostic correlation.
    Choi YL; Kim J; Kwon MJ; Choi JS; Kim TJ; Bae DS; Koh SS; In YH; Park YW; Kim SH; Ahn G; Shin YK
    Histol Histopathol; 2007 Nov; 22(11):1185-95. PubMed ID: 17647191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of gene expression in stage I serous tumors identifies critical pathways altered in ovarian cancer.
    Chien J; Fan JB; Bell DA; April C; Klotzle B; Ota T; Lingle WL; Gonzalez Bosquet J; Shridhar V; Hartmann LC
    Gynecol Oncol; 2009 Jul; 114(1):3-11. PubMed ID: 19410283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.